Vanguard Group Inc. Purchases 92,580 Shares of Intellia Therapeutics, Inc. (NTLA)

Vanguard Group Inc. increased its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 10.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 997,288 shares of the company’s stock after buying an additional 92,580 shares during the period. Vanguard Group Inc. owned about 2.76% of Intellia Therapeutics worth $15,957,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Neuberger Berman Group LLC increased its stake in shares of Intellia Therapeutics by 14.9% during the second quarter. Neuberger Berman Group LLC now owns 49,517 shares of the company’s stock worth $792,000 after buying an additional 6,431 shares during the period. American Century Companies Inc. purchased a new stake in shares of Intellia Therapeutics during the second quarter worth approximately $583,000. Bank of Montreal Can increased its stake in shares of Intellia Therapeutics by 1,031.7% during the second quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock worth $127,000 after buying an additional 7,222 shares during the period. Wells Fargo & Company MN increased its stake in shares of Intellia Therapeutics by 176.1% during the second quarter. Wells Fargo & Company MN now owns 30,215 shares of the company’s stock worth $483,000 after buying an additional 19,270 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in shares of Intellia Therapeutics by 73.0% during the second quarter. Bank of New York Mellon Corp now owns 54,802 shares of the company’s stock worth $876,000 after buying an additional 23,126 shares during the period. Hedge funds and other institutional investors own 47.43% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Vanguard Group Inc. Purchases 92,580 Shares of Intellia Therapeutics, Inc. (NTLA)” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://stocknewstimes.com/2017/11/18/vanguard-group-inc-purchases-92580-shares-of-intellia-therapeutics-inc-ntla.html.

NTLA has been the topic of a number of recent research reports. Jefferies Group LLC restated a “buy” rating and set a $36.00 target price on shares of Intellia Therapeutics in a research note on Saturday, July 22nd. Chardan Capital reiterated a “buy” rating and issued a $20.00 price target (up from $19.00) on shares of Intellia Therapeutics in a research note on Wednesday, August 2nd. Barclays PLC reiterated a “buy” rating on shares of Intellia Therapeutics in a research note on Sunday, November 5th. Zacks Investment Research upgraded shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. Finally, ValuEngine upgraded shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 22nd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $30.17.

Intellia Therapeutics, Inc. (NASDAQ NTLA) opened at $19.90 on Friday. Intellia Therapeutics, Inc. has a one year low of $10.83 and a one year high of $33.34.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Tuesday, October 31st. The company reported ($0.44) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.06. The company had revenue of $7.30 million for the quarter, compared to analyst estimates of $5.83 million. Intellia Therapeutics had a negative net margin of 215.92% and a negative return on equity of 28.01%. The firm’s revenue was up 49.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.22) earnings per share. sell-side analysts expect that Intellia Therapeutics, Inc. will post -1.68 earnings per share for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics, Inc. (NASDAQ:NTLA).

Institutional Ownership by Quarter for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply